8+ hour, 44+ min ago  (181+ words) Does infusion timing matter in TNBC? Early-day pembrolizumab may boost p CR and cut recurrences, prompting new scheduling questions. To evaluate whether the timing of IO infusion timing is associated with pathological complete response (p CR), recurrence, survival in patients…...

8+ hour, 44+ min ago  (103+ words) Clonal blood mutations common in breast cancer may sharply raise heart failure risk after anthracyclines, urging better screening and personalized cardio-oncology care. Seth A. Wander, MD, Ph D; Ruta D. Rao, MD Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD Seth A. Wander, MD, Ph…...

1+ day, 1+ hour ago  (80+ words) Seth A. Wander, MD, Ph D; Ruta D. Rao, MD Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD Seth A. Wander, MD, Ph D; Kate Baxstrom, MD Aman Chauhan, MD, MBBS; Jonathan Strosberg, MD; Sylvia L. Asa, MD, Ph D William J. Gradishar, MD, FASCO, FACP; Rebecca…...

1+ day, 5+ hour ago  (211+ words) Phase 3 results support anbenitamab plus albumin-bound docetaxel as a new treatment option in HER2-positive breast cancer across disease stages. Results from a phase 3 clinical trial evaluating anbenitamab (KN026; Ennituo) plus docetaxel for injection albumin-bound (HB1801) in patients with HER2-positive breast cancer met…...

3+ day, 3+ hour ago  (156+ words) Zovegalisib plus fulvestrant demonstrated an objective response rate of 38. 7% and a median progression-free survival of 10. 3 months in PIK3 CA-mutant HR+/HER2" advanced breast cancer in the Re Discover trial. Previously treated adult patients with advanced HR+/HER2" breast cancer and PIK3 CA mutation per…...

1+ week, 8+ hour ago  (112+ words) Data from the phase 3 SENOMAC trial showed that omitting completion ALND led to non-inferior 5-year OS and lower arm morbidity for patients with breast cancer. During the conference, Cancer Network" spoke with Jana de Boniface, MD, adjunct professor in the…...

1+ week, 2+ day ago  (368+ words) Giredestrant improved invasive disease-free survival vs endocrine therapy for patients with ER+, HER2" early breast cancer in the phase 3 lid ERA trial. The FDA has both accepted and granted priority review to a new drug application (NDA) for giredestrant as an…...

1+ week, 2+ day ago  (155+ words) GLP-1 receptor agonist use was tied to reduced HR+/HER2" breast cancer incidence and improved overall survival in non-diabetic women with elevated BMI. Overall survival (OS) results were notable across all strata analyzed. In the full matched cohort of 148, 709 women, GLP…...

1+ week, 4+ day ago  (350+ words) For patients with early breast cancer receiving chemotherapy, the use of a dexamethasone mouthwash did not significantly reduce the incidence of oral mucositis. The use of dexamethasone mouthwash did not significantly reduce all-grade oral mucositis for patients with early breast…...

3+ week, 4+ day ago  (610+ words) Based on data from the DESTINY-Breast11 and DESTINY-Breast05 trials, the FDA has approved T-DXd as neoadjuvant and adjuvant treatment for patients with HER2-positive early breast cancer. The FDA has approved fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) as neoadjuvant or adjuvant treatment for…...